PCRX logo

PCRX
Pacira BioSciences Inc

1,566
Mkt Cap
$906.28M
Volume
438,990.00
52W High
$27.64
52W Low
$18.80
PE Ratio
188.39
PCRX Fundamentals
Price
$23.53
Prev Close
$23.04
Open
$23.14
50D MA
$23.51
Beta
0.32
Avg. Volume
515,202.12
EPS (Annual)
$0.1562
P/B
1.41
Rev/Employee
$876,249.70
$1,345.47
Loading...
Loading...
News
all
press releases
Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price
Royal Bank Of Canada raised their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a research report on Friday...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Zacks·13d ago
News Placeholder
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade...
MarketBeat·14d ago
News Placeholder
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Key PointsCFO Shawn Cross exercised and sold 12,941 shares on April 23, 2026, for a transaction value of ~$326,000 at around $25.16 per share...
Nasdaq News: Markets·14d ago
News Placeholder
Needham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00
Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday...
MarketBeat·14d ago
News Placeholder
Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by...
MarketBeat·14d ago
News Placeholder
Pacira BioSciences Q1 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) reported first-quarter 2026 results that management said reflect continued momentum under its 5x30 strategy, highlighted by year-over-year growth across its three...
MarketBeat·14d ago
News Placeholder
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Pacira BioSciences Q1 2026 Earnings Call Transcript
read more...
Benzinga·14d ago
News Placeholder
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
Zacks·18d ago
<
1
2
...
>

Latest PCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.